AQR Capital Management LLC Trims Stock Position in Pulse Biosciences, Inc. (NASDAQ:PLSE)

AQR Capital Management LLC cut its position in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) by 13.6% during the second quarter, Holdings Channel.com reports. The firm owned 11,195 shares of the company’s stock after selling 1,766 shares during the quarter. AQR Capital Management LLC’s holdings in Pulse Biosciences were worth $125,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of PLSE. Vanguard Group Inc. raised its stake in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after purchasing an additional 189,227 shares during the period. Griffin Asset Management Inc. raised its stake in Pulse Biosciences by 15.7% during the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock worth $2,616,000 after purchasing an additional 40,700 shares during the period. Westside Investment Management Inc. raised its stake in shares of Pulse Biosciences by 97.8% in the 2nd quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after acquiring an additional 31,440 shares during the period. PNC Financial Services Group Inc. purchased a new stake in shares of Pulse Biosciences in the 4th quarter valued at approximately $242,000. Finally, Cetera Advisors LLC purchased a new stake in shares of Pulse Biosciences in the 1st quarter valued at approximately $109,000. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Stock Down 2.6 %

NASDAQ PLSE opened at $17.30 on Friday. Pulse Biosciences, Inc. has a 52 week low of $3.78 and a 52 week high of $22.69. The stock has a market capitalization of $1.06 billion, a PE ratio of -21.36 and a beta of 1.74. The firm has a 50 day moving average of $17.87 and a two-hundred day moving average of $13.62.

Analyst Ratings Changes

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a research note on Friday, September 20th.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.